GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis

Xichun Xia,Guangchao Cao,Guodong Sun,Leqing Zhu,Yixia Tian,Yueqi Song,Chengbin Guo,Xiao Wang,Jingxiang Zhong,Wei Zhou,Peng Li,Hua Zhang,Jianlei Hao,Zhizhong Li,Liehua Deng,Zhinan Yin,Yunfei Gao
DOI: https://doi.org/10.1172/jci129269
IF: 19.456
2020-08-24
Journal of Clinical Investigation
Abstract:Psoriasis is a severe disease associated with the disturbance of metabolism and inflammation, but the molecular mechanisms underlying these aspects of psoriasis pathology are poorly understood. Here, we report that glutaminase 1–mediated (GLS1-mediated) glutaminolysis was aberrantly activated in patients with psoriasis and in psoriasis-like mouse models, which promoted Th17 and γδ T17 (IL-17A–producing γδ T) cell differentiation through enhancement of histone H3 acetylation of the <i>Il17a</i> promoter, thereby contributing to the immune imbalance and development of psoriasis. We further demonstrate that mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease was constitutively active in psoriatic CD4<sup>+</sup> and γδ T cells, thereby supporting GLS1 expression by stabilizing c-Jun, which directly binds to the GLS1 promoter region. Blocking the activity of either GLS1 or MALT1 protease resolved Th17 and γδ T17 cell differentiation and epidermal hyperplasia in the psoriasis-like mouse models. Finally, IL-17A enhanced GLS1 expression via the MALT1/cJun pathway in keratinocytes, resulting in hyperproliferation of and chemokine production by keratinocytes. Our findings identify the role of the MALT1/cJun/GLS1/glutaminolysis/H3 acetylation/T17 axis in psoriasis pathogenesis and reveal potential therapeutic targets for this disease.
medicine, research & experimental
What problem does this paper attempt to address?